56S1 Stock Chart & Stats
€197.90
€7.00(4.36%)
At close: 4:00 PM EDT
€197.90
€7.00(4.36%)
Day’s Range― - ―
52-Week Range€151.50 - €223.50
Previous CloseN/A
Volume28.00
Average Volume (3M)50.00
Market Cap
€20.67B
Enterprise Value€19.88K
Total Cash (Recent Filing)€203.90M
Total Debt (Recent Filing)€2.40B
Price to Earnings (P/E)71.7
Beta1.12
Next Earnings
Oct 22, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume63
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€240.00Price Target Upside21.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.02
Revenue Forecast (FY)€3.13B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp TTM revenue rebound indicates that customer demand and bioprocessing activity are recovering meaningfully. Sustained growth would improve operating leverage, support reinvestment in the product portfolio, and strengthen the company’s position across biologics manufacturing workflows.
Improved LeverageA materially lower debt-to-equity ratio gives Sartorius Stedim Biotech a more balanced capital structure and greater financial flexibility. This can support continued investment in capacity and innovation while reducing the balance-sheet pressure associated with its earlier leverage profile.
Recurring Consumables ModelFrequent replenishment of consumables creates a recurring revenue stream alongside equipment sales. The installed base can therefore support repeat purchasing over multiple production cycles, improving customer retention and making revenue less dependent on occasional capital-equipment projects.
Bears Say
Margin Recovery IncompleteProfitability remains well below prior peak levels despite the revenue rebound, showing that recovery has not yet translated fully into earnings. Persistently lower net margins could limit internal funding for growth and leave results more sensitive to operating costs and product mix.
Weak Cash ConversionLow free-cash-flow conversion means accounting earnings are not yet translating efficiently into discretionary cash. Although free cash flow has improved, inconsistent conversion can constrain debt reduction, investment capacity, and shareholder returns until cash generation becomes more dependable.
Returns Remain ModestModest returns on equity indicate that the enlarged equity base is not yet producing the profitability achieved in earlier years. Combined with sizable absolute debt, this leaves financial performance in a rebuilding phase and may limit capital-allocation flexibility.
Sartorius Stedim Biotech News
56S1 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €151.50 and its highest was €223.50 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €20.67B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 23 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported €1.25 earnings per share for the quarter, missing the consensus estimate of €1.263 by -€0.013.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.19.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.25 in its last earnings report, missing expectations of €1.263. Following the earnings report the stock price went down -0.987%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in DE:56S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
56S1 Stock 12 Month Forecast
Average Price Target
€240.00
▲(21.27% Upside)